KNOWLEDGE
DRIVES
EVERYTHING

The 2025 Sydney Falk Foundation Symposium – Immune-Mediated Diseases of the GI Tract – Treat to Target Approach – brought together global experts to explore the evolving landscape of gastrointestinal immunopathology, including eosinophilic oesophagitis, inflammatory bowel disease (IBD), and microscopic colitis.
Through expert lectures and interactive sessions, the symposium showcased cutting-edge research, novel therapies, and practical strategies that extended the treat to target paradigm beyond IBD. The meeting fostered collaborative learning and global exchanges, advancing the understanding and management of immune-mediated GI diseases.
Whether you missed the meeting or attended and wish to review the content, you can access it here at your convenience. The opinions expressed by the speakers do not necessarily reflect those of Dr Falk Pharma Australia, and some therapeutic interventions discussed may not currently be approved by the TGA.

WATCH THE SESSIONS

Play Video

Welcome

Professor Rupert Leong
Sydney Australia

Session 1: Is treat to target the ideal strategy in immune-mediated GI diseases (IBD, EoE, microscopic colitis)? Debate

Chairs: Professor Gerald Holtmann, Brisbane Australia; Professor Michael A. Kamm, Melbourne Australia
Play Video

1.1 Debate − Pro: Is treat to target the ideal strategy in immune-mediated GI diseases (IBD, EoE, microscopic colitis)?

Professor Axel Dignass
Frankfurt Germany
Play Video Play Video
1.1 Debate − Pro: Is treat to target the ideal strategy in immune-mediated GI diseases (IBD, EoE, microscopic colitis)?
Professor Axel Dignass, Frankfurt Germany
Play Video Play Video
1.2 Debate − Con: Is treat to target the ideal strategy in immune-mediated GI diseases (IBD, EoE, microscopic colitis)?
Professor Peter Gibson, Melbourne Australia
Play Video Play Video
1.3 Panel discussion: Moderator: Dr Lena Thin, Murdoch, Australia
Panel: Professor Axel Dignass, Frankfurt Germany; Professor Peter Gibson, Melbourne Australia; Associate Professor Gregory Moore, Clayton Australia; Professor Dan Turner, Jerusalem Israel
Play Video Play Video
1.4 Summary
Professor Richard Gearry, Christchurch New Zealand

Session 2: IBD strategies and assessments

Chairs: Professor Richard Gearry, Christchurch New Zealand; Professor Dr Ailsa Hart, London Great Britain
Play Video

2.1 Holistic patient assessment: Depression, fatigue, pain, social integration - how does it impact therapy?

Akhilesh Swaminathan PhD
Christchurch New Zealand
Play Video Play Video
2.1 Holistic patient assessment: Depression, fatigue, pain, social integration – how does it impact therapy?
Akhilesh Swaminathan PhD, Christchurch New Zealand
Play Video Play Video
2.3 IUS and calprotectin: Greater cost effectiveness over MRE and colonoscopy?
Dr Yoon-Kyo An, Brisbane Australia
Play Video Play Video
2.4 Early surgery in Crohn’s disease: Underused?
Professor Dr Willem A. Bemelman, Amsterdam The Netherlands
Play Video Play Video
2.5 Panel discussion
Dr Yoon-Kyo An, Brisbane Australia; Professor Dr Willem A. Bemelman, Amsterdam The Netherlands; Professor Richard Gearry, Christchurch New Zealand; Professor Dr Ailsa Hart, London Great Britain; Professor Dr Stefan Schreiber, Kiel Germany; Akhilesh Swaminathan PhD, Christchurch New Zealand

Session 3: Old and new drugs in IBD

Chairs: Professor Maria T. Abreu, Los Angeles United States; Dr Aviv Pudipeddi, Sydney Australia
Play Video

3.1 5-ASA optimization & combination oral/topical

Professor Dr Britta Siegmund
Berlin Germany
Play Video Play Video
3.1 5-ASA optimization & combination oral/topical
Professor Dr Britta Siegmund, Berlin Germany
Play Video Play Video
3.2 The case for thiopurines (including thioguanine)
Associate Professor Mark Ward, Melbourne Australia
Play Video Play Video
3.3 JAKi and S1P: Efficacy and safety
Dr David T. Rubin, Chicago United States
Play Video Play Video
3.4 Anti-IL23 (including reimbursement barriers in Australia)
Dr Taku Kobayashi, Tokyo Japan
Play Video Play Video
3.5 Microbial therapies: Prebiotic, postbiotic and FMT
Dr Damjana Bogatic, Adelaide Australia

Session 4: IBD into the future

Chairs: Professor Jane Andrews, Adelaide; Professor Charles N. Bernstein, Manitoba Canada
Play Video

4.1 Epidemiology: Compounding prevalence

Professor Charles N. Bernstein
Manitoba Canada
Play Video Play Video
4.1 Epidemiology: Compounding prevalence
Professor Charles N. Bernstein, Manitoba Canada
Play Video Play Video
4.2 How to deal with the tsunami of drug use/resource utilization
Professor Johan Burisch, Hvidovre Denmark
Play Video Play Video
4.3 Models of care, innovations (remote) in IBD and non-IBD
Sang H. Park MD, PhD, Seoul Republic of Korea
Play Video Play Video
4.4 Treatment options, treatment changes: What, when, why
Professor Remo Panaccione, Calgary Canada
Play Video

Day 1 - Closing remarks

Professor Jane Andrews
Adelaide Australia

Session 5: Eosinophilic esophagitis

Chairs: Dr Yoon-Kyo An, Brisbane Australia; Professor Susan Connor, Sydney Australia
Play Video

5.1 The role of AI in endoscopy of EoE

Prof Dr Helmut Messmann
Augsburg Germany
Play Video Play Video
5.1 The role of AI in endoscopy of EoE
Prof Dr Helmut Messmann, Augsburg Germany
Play Video Play Video
5.2 EoE symptoms: Inflammation versus fibrostenosis
Professor Santosh Sanagapalli, Sydney Australia
Play Video Play Video
5.3 EoE therapy: Steroids versus biological agents
Dr Luc Biedermann, Zurich, Switzerland
Play Video Play Video
5.4 EoE diet: Role of diet in EoE therapy?
Dr Emma Halmos, Melbourne Australia
Play Video Play Video
5.5 Maintenance therapy: Treat to target?
Associate Professor Hamish Philpott, Adelaide Australia
Play Video Play Video
5.6 Case discussion

Session 6: Diarrhea & microscopic colitis: Treat to target paradigm

Chairs: Professor Jane Andrews, Adelaide Australia; Dr David T. Rubin, Chicago United States
Play Video

6.1 The diarrheal world: Causes & diagnostic approach

Professor Gillian Watermeyer
Cape Town South Africa
Play Video Play Video
6.1 The diarrheal world: Causes & diagnostic approach
Professor Gillian Watermeyer, Cape Town South Africa
Play Video Play Video
6.2 Microscopic colitis: Epidemiology, risk factors, treatment
Professor Peter Katelaris, Sydney Australia
Play Video Play Video
6.3 Eosinophilic enteritis & colitis
Associate Professor Rebecca Burgell, Melbourne Australia
Play Video Play Video
6.4 Checkpoint inhibitor colitis
Dr Andrew D. Buckle, Launceston Australia
Play Video Play Video
6.5 Presentation of poster awards
Play Video Play Video
6.6 Cases & discussion presented by registrars

Session 7: Strictures in Crohn’s disease

Chairs: Professor Dr Raja Affendi Raja Ali, Selangor Malaysia, Professor Dr Gerhard Rogler, Zurich Switzerland
Play Video

7.1 Clinical, imaging and biomarker assessment of Crohn’s disease strictures and applying a treat to target approach

Professor Rupert Leong
Sydney Australia
Play Video Play Video
7.1 Clinical, imaging and biomarker assessment of Crohn’s disease strictures and applying a treat to target approach
Professor Rupert Leong, Sydney Australia
Play Video Play Video
7.2 Treatment of strictures in Crohn’s disease 2025 – From anti fibrotics to diet
Professor Dr Iris Dotan, Petah Tikva Isreal
Play Video Play Video
7.3 Endoscopic approaches to strictures and combination with advanced therapy
Dr John Chetwood, Melbourne Australia
Play Video Play Video
7.4 Strictureplasty versus resection – Which one and how?
Professor Dr Willem A. Bemelman, Amsterdam The Netherlands

Session 8: Other opportunities to optimize; Comorbidities in IBD

Chairs: Professor Rupert Leong, Sydney Australia; Dr Kate D. Lynch, Adelaide Australia
Play Video

8.1 Obesity (including management)

Dr Patricia Kaazan
Adelaide Australia
Play Video Play Video
8.1 Obesity (including management)
Dr Patricia Kaazan, Adelaide Australia
Play Video Play Video
8.2 Cardiovascular comorbidities and how to assess them
Dr Ashwin N. Ananthakrishnan MD, MPH, Boston United States
Play Video Play Video
8.3 Mortality in IBD: Cancer, clots, infections
Dr Kate D. Lynch, Adelaide Australia
Play Video Play Video
8.4 Primary sclerosing cholangitis
Dr Vineet Ahuja, New Delhi India
Play Video Play Video
8.5 Anemia
Professor Jane Andrews, Adelaide Australia
Play Video Play Video
8.6 Fatigue
Professor Fernando Magro Dias, Porto Portugal
Play Video

Day 2 - Closing remarks

Professor Rupert Leong
Sydney Australia

SCIENTIFIC ORGANISATION

Professor Jane Andrews
Australia
Professor Dr. Axel Dignass
Germany
Professor Richard Gearry
New Zealand
Professor Rupert Leong
Australia
Professor Dr. Gerhard Rogler
Switzerland
Professor Jane Andrews
Australia
Professor Dr. Axel Dignass
Germany
Professor Richard Gearry
New Zealand
Professor Rupert Leong
Australia
Professor Dr. Gerhard Rogler
Switzerland

This content is intended for Healthcare Professionals only.
Copyright © 2025 Dr Falk Pharma Australia Pty Ltd. ABN 40 631 091 131. 9 Help Street, Chatswood NSW 2067.
Website: www.drfalkpharma.com.au Tel: 1800 DRFALK (1800 373 255). Email: admin@drfalkpharma.com.au
Date of preparation May 2025. DFR354. COR-2025-1484.

DR. FALK PHARMA AUSTRALIA – Scientific & Educational Excellence Partner of FALK FOUNDATION e.V.